• What Scientists Actually Need From AI

    Bio-IT World | A target looks good on paper. The literature supports it, the mechanism is plausible, and three independent groups have published findings that point the same direction. There is also a contradictory result, which someone found early, mentioned in a meeting, and set aside because it seemed less persuasive than the rest. The team builds its case, and the program advances. Years later, in preclinical validation or, worse, in the clinic, that discarded finding turns out to have been the important one.

    Aug 28, 2026

  • Follow the Money: Biological Foundation Models, Automated Bioanalysis, Predictive Cancer Care

    Bio-IT World | LifeMine Therapeutics advances a novel treatment for organ transplantation; InduPro doses the first patient in a phase 1 study of a bispecific antibody-drug conjugate; Remepy advances an AI-enabled treatment for Parkinson’s disease; and more.

    Aug 26, 2026

  • New CRISPR Screening Service, Calla Lily Joins Wellcome Leap’s Program, Baylor College to Establish Xenoliver Transplant Center

    Bio-IT World | Northwest Biotherapeutics enters a non-binding Memorandum of Understanding with the Saudi Pharmaceutical Industries and Medical Appliance Company; Novogene Europe expands its single-cell RNA sequencing capability at its Cambridge Omics Centre; and more.

    Aug 25, 2026

  • Psychedelics Reveal Immune Signatures Linked to Rapid Depression Relief

    Bio-IT World | Psychedelic drugs, such as psilocybin and ketamine, could offer a faster, more biologically targeted approach to treating depression in people with cancer, while emerging research suggests immune-system biomarkers may help identify which patients are most likely to respond. Researchers from The University of Texas MD Anderson Cancer Center are investigating how the brain and immune system interact in cancer-associated depression.

    Aug 20, 2026

  • Multiomics Study Connects Clinical Phenotypes to Molecular Signatures in Down Syndrome

    Bio-IT World | A comprehensive multiomics analysis is shedding new light on why people with Down syndrome experience vastly different health outcomes, offering evidence that molecular profiling could lay the foundation for a more personalized approach to managing the genetic condition.

    Aug 19, 2026

  • Quality Leaders Warn Against Digitizing Broken Processes

    Bio-IT World | At last week's Bioprocessing Summit, Gilead Sciences' Senior Vice President of Global Quality Anthony Mire-Sluis opened the Wednesday plenary session with a blunt warning to an industry rushing toward AI: digitizing a bad process just gets you a bad process, faster and more expensive to fix.

    Aug 18, 2026

  • The End of the ‘One-Size-Fits-All’ Parkinson’s Diagnosis: Why 2026 Is the Year Neurology Goes High-Resolution

    Bio-IT World | For over 200 years, neurology has relied on James Parkinson’s 1817 clinical observations as the definitive anchor for understanding Parkinson’s disease. Resting tremor, stooped posture, and a shuffling gait have long served as the standard diagnostic triad. Yet, Parkinson’s is far from a monolithic motor disease.

    Aug 14, 2026

  • Human Longevity Launches $600 Whole Genome

    Bio-IT World | Human Longevity last week announced the availability of Genomics for All, a clinical-grade whole genome sequencing product priced at $599. Genomics for All sequences the entire genome at 30x clinical-grade depth and is capable of identifying inherited disease risk across more than 10,000 genetic variants.

    Aug 13, 2026

  • AI-engineered Vaccine Approach Could End Cycle of Variant Chasing

    Bio-IT World | A spin-out company of the University of Cambridge is developing a pipeline technology to serve as the computer chip for a whole new class of vaccines covering a family or group of viruses targeted at different stages of their lifecycle. DIOSynVax, short for Digital Immune-Optimized Synthetic vaccines, brings together genomics, synthetic biology, artificial intelligence (AI), and immunology to design broadly protective vaccine antigens that are compatible with most vaccine delivery systems.

    Aug 12, 2026